Many companies in the pharmaceutical industry are working feverishly to bring mRNA preparations onto the market, even for harmless diseases. However, serious side effects, including dangerous forms of the disease that the “vaccination” was supposed to prevent, are now already occurring in the first phases of clinical trials.
Source: Dr Peter F. Mayer, TKP.at, 13 Dec. 2024
The respiratory syncytial virus (RSV) is basically a common cold. There are already paediatric vaccines for it, as one of the 70 vaccinations that are now being given to children. Moderna is working on an mRNA preparation for infants, but there are now apparently problems with it, as reported here.
The FDA has just published an information document for the December 12, 2024 meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) entitled “Considerations for the Safety of Respiratory Syncytial Virus (RSV) Vaccines in Paediatric Populations”.
The document states that in July 2024, a Phase 1 study evaluating the safety, tolerability and immunogenicity of two of Moderna’s RSV vaccine candidates (mRNA-1365 and mRNA-1345) in infants aged 5 to 8 months was interrupted following reports of five severe to very severe cases of lower respiratory tract infection (LRTI) caused by RSV:
During the study, an imbalance in severe RSV cases was identified in participants aged 5 to <8 months who received the lower mRNA vaccine dose, based on a pre-specified study dropout criterion. In Cohorts 3 and 4, five (5) cases (12.5% of participants) of clinically significant (CS) severe/very severe RSVwere identifiedin the vaccine groups (all had received 1 or 2 doses of a 3-dose regimen), compared with one (1) case (5% of participants) in the placebo group. The percentage of participants with symptomatic RSV disease in Cohorts 3 and 4 who progressed to severe disease was 26.3% in the vaccine groups compared to 8.3% in the placebo group.
One of the candidates in the paused study was mRNA-1345 (mRESVIA), which had already been approved by the FDA for adults 60 years and older, although no genotoxicity, oncogenicity or long-term safety studies were available:
This is another case where mRNA injections fail to fulfil essential safety requirements. Instead of protecting infants from RSV, these novel injections appear to have exacerbated the severity of infections. Instead of continuing the development and introduction of this flawed mRNA platform, our health authorities should prioritise measures that do not usually lead to serious adverse events.
The data is impressive: 12.5 % of the vaccinated children developed severe or very severe RSV disease, compared to only 5 % in the placebo group.
In addition, 26.3% of the vaccinated participants developed severe disease, which is in stark contrast to the 8.3% in the placebo group.
The FDA, which granted fast-track status to the vaccine in 2021, said the data had “unclear implications for ongoing and future paediatric development of other non-live attenuated RSV vaccines”.
Unclear effects
The implications of this data are serious and make for uncomfortable comparisons with the failed vaccine trials against RSV in the 1960s.
These earlier studies were cancelled after two infants tragically died of RSV disease following administration of a formalin-inactivated RSV vaccine.
This catastrophe led to the discovery of vaccine-acquired respiratory disease (VAERD), a disease in which vaccination paradoxically exacerbates the severity of a viral infection rather than preventing it.
To make matters worse, similar mRNA-RSV vaccines are being tested on pregnant women to transfer protective antibodies to their babies.
RSV vaccinations and especially new preparations have already led to serious illnesses and even deaths. See the corresponding links to the TKP articles below.
